⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6889514 | 0.83 | GRIN2D (0.31) | — | |
| SCHEMBL17132553 | 0.82 | — | — | |
| SCHEMBL24086616 | 0.77 | SLC22A2 (0.39) | — | |
| SCHEMBL17973823 | 0.69 | — | — | |
| SCHEMBL10160187 | 0.63 | — | — | |
| SCHEMBL24127009 | 0.63 | — | — | |
| SCHEMBL19766568 | 0.63 | — | — | |
| SCHEMBL25019038 | 0.63 | — | — | |
| SCHEMBL130746 | 0.62 | — | — | |
| SCHEMBL10097032 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-11738026-B2 | Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor | INCYTE CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738026-B2 | Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor | INCYTE CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702407-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023116902-A1 | SOS1 INHIBITOR | 北京望实智慧科技有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20230137932-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20210154195-A1 | COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR | INCYTE CORPORATION | 2021-05-27 | — | — | US | disclosed |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
| US-10710980-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190161474-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2019-05-30 | — | — | US | disclosed |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-01-25 | — | — | US | disclosed |